NextCure, Inc. (NXTC) - Q1 2026 10-Q Summary
Business Context and Reporting Period
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer patients. This report covers the quarterly period ended March 31, 2026. The company operates as a single segment (Life Sciences) and has not generated any product revenue to date. A 1-for-12 reverse stock split was effectuated on July 14, 2025, and all share data has been adjusted retrospectively.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(9.8) million | $(11.0) million |
| Net Loss Per Share (Basic & Diluted) | $(1.87) | $(4.70) |
| Operating Expenses | $10.1 million | $11.6 million |
| Cash, Cash Equivalents & Marketable Securities | $29.7 million | $43.6 million (approx. based on prior period cash + securities) |
| Net Cash Used in Operating Activities | $(13.4) million | $(13.0) million |
| Accumulated Deficit | $(445.8) million | $(391.1) million (as of Mar 31, 2025) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $1.5 million year-over-year. Research and Development (R&D) expenses declined by $1.1 million, and General and Administrative (G&A) expenses declined by $0.5 million.
- R&D Drivers: The decrease in R&D was driven by lower costs for deprioritized programs (NC410 and NC525) and reduced internal personnel costs (specifically stock-based compensation). These savings were partially offset by new costs associated with the SIM0505 program acquired in Q2 2025.
- Stock-Based Compensation: Total stock-based compensation expense dropped significantly from $1.4 million in Q1 2025 to $0.3 million in Q1 2026.
- Liquidity: Cash and cash equivalents decreased from $26.0 million at year-end 2025 to $15.2 million at March 31, 2026, primarily due to operating cash burn.
Guidance, Outlook, and Risks
- Going Concern: Management has raised substantial doubt regarding the company's ability to continue as a going concern for one year following the issuance of these financial statements. Current cash resources ($29.7 million) are not sufficient to fund operations for the next 12 months.
- Capital Needs: The company expects to need additional capital to extend its runway beyond the first half of 2027 to advance lead programs SIM0505 and LNCB74. Failure to raise funds may result in cost-cutting, program delays, or workforce reductions.
- Recent Financing: In Q1 2026, the company raised approximately $1.2 million through an At-The-Market (ATM) offering. In late 2025, a private placement raised $20.3 million.
- Clinical Progress:
- SIM0505: Received FDA Fast Track Designation for platinum-resistant ovarian cancer in April 2026. Dose optimization phase initiated in May 2026.
- LNCB74: Phase 1 trial ongoing; proof-of-concept data reporting delayed to the second half of 2026 due to protocol amendments and patient backfilling.
- Risks: Key risks include the inability to secure additional financing, clinical trial failures, regulatory delays, and the need to partner or license out programs if funding is insufficient.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and current burn rate of ~$13.4 million per quarter.
- ATM Capacity: Confirm remaining capacity under the $14.5 million Wainwright ATM agreement and current market conditions for equity sales.
- License Obligations: Review the Zaiming License Agreement for upcoming milestone payments (e.g., Phase 2 initiation) and royalty structures.
- Program Prioritization: Assess the status of deprioritized programs (NC410, NC525) and the likelihood of securing partners for them.
- Stock Dilution: Monitor the impact of outstanding pre-funded warrants (1.7 million shares) and options on future share count and per-share value.